BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/7/2018 9:21:44 AM | Browse: 943 | Download: 1375
 |
Received |
|
2018-03-25 07:05 |
|
Peer-Review Started |
|
2018-03-25 12:54 |
|
To Make the First Decision |
|
2018-04-11 01:24 |
|
Return for Revision |
|
2018-04-13 02:38 |
|
Revised |
|
2018-08-03 14:56 |
|
Second Decision |
|
2018-08-10 08:37 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2018-08-11 22:42 |
|
Articles in Press |
|
2018-08-11 22:42 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2018-08-24 18:16 |
|
Typeset the Manuscript |
|
2018-09-04 07:37 |
|
Publish the Manuscript Online |
|
2018-09-07 09:21 |
| ISSN |
2220-6124 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Urology & Nephrology |
| Manuscript Type |
Basic Study |
| Article Title |
A small molecule fibrokinase inhibitor in a model of fibropolycystic hepatorenal disease
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Prani Paka, Brian Huang, Bin Duan, Jing-Song Li, Ping Zhou, Latha Paka, Michael A Yamin, Scott L Friedman, Itzhak D Goldberg and Prakash Narayan |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Prakash Narayan, PhD, Research Scientist, Department of Research and Development, Angion Biomedica Corp., 51 Charles Lindbergh Blvd., Uniondale, NY 11553, United States. pnarayan@angion.com |
| Key Words |
Congenital hepatic fibrosis; Cyst; Fibrosis; Autosomal recessive polycystic kidney disease; Kidney; Liver; Therapy |
| Core Tip |
In autosomal recessive polycystic kidney disease (ARPKD)-congenital hepatic fibrosis (CHF), a genetically acquired and congenital disease, approximately 20-30% of affected patients succumb within the first 1-2 mo of life, with pulmonary insufficiency secondary to renal enlargement as the primary cause of death. For children, nephrectomy and dialysis or kidney liver transplant is often warranted by approximately ten years of age. Other than transplantation, there is no cure for ARPKD-CHF. We report that platelet-derived growth factor and vascular endothelial growth factor are the intermediaries between the cystic and fibrotic components of progressive fibropolycystic disease and ANG3070, a novel dual kinase inhibitor therapy that may serve as an interesting bridge toward hepato-renal transplantation in patients with ARPKD-CHF. |
| Publish Date |
2018-09-07 09:21 |
| Citation |
Paka P, Huang B, Duan B, Li JS, Zhou P, Paka L, Yamin MA, Friedman SL, Goldberg ID, Narayan P. A small molecule fibrokinase inhibitor in a model of fibropolycystic hepatorenal disease. World J Nephrol 2018; 7(5): 96-107 |
| URL |
http://www.wjgnet.com/2220-6124/full/v7/i5/96.htm |
| DOI |
http://dx.doi.org/10.5527/wjn.v7.i5.96 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
